Press Releases

Press Releases
Publications
Media Coverage
Events

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Subscribe to email alert

Thank you! Your submission has been received!
Something went wrong while submitting the form.
Navigation
CompanyOur ProductPipelineAbout strokeMedia
Contact Us
ContactFollow us on LinkedInFollow us on Twitter

Acticor Biotech
Wojo Building
82, avenue du Maine
75014 Paris

+33 (0)6 76 23 38 13

© 2021 Acticor Biotech SA
Legal mentionsPrivacy Policy
email:
contact@acticor-biotech.com